Melatonin acts synergistically with pazopanib against renal cell carcinoma cells through p38 mitogen-activated protein kinase-mediated mitochondrial and autophagic apoptosis.

Chien-Pin LaiYong-Syuan ChenTsung-Ho YingCheng-Yen KaoHui-Ling ChiouShao-Hsuan KaoYi-Hsien Hsieh

Published in: Kidney research and clinical practice (2023)

The combination of melatonin and pazopanib inhibits the growth of RCC cells by inducing p38MAPK-mediated mitochondrial and autophagic apoptosis. Therefore, melatonin might be a potential adjuvant that could act synergistically with pazopanib for RCC treatment.

Keyphrases

cell cycle arrest
cell death
oxidative stress
induced apoptosis
endoplasmic reticulum stress
metastatic renal cell carcinoma
renal cell carcinoma
pi k akt
early stage
single cell
cell therapy
stem cells
cell proliferation
mesenchymal stem cells
signaling pathway
replacement therapy
climate change